Initial Phase 1 Dose Escalation Data of ORIC-114 in

CNS activity observed at multiple dose levels, including the first reported confirmed CNS complete response by an EGFR exon 20 inhibitor in a patient with...

Related Keywords

United States ,California ,South San Francisco ,San Diego ,Pratik Multani ,Jacobm Chacko ,Securities Exchange ,Pharmaceuticals Inc ,European Society Of Medical Oncology ,Exchange Commission ,Nasdaq ,Linkedin ,European Society ,Medical Oncology ,Escalation Data ,Pharmacokinetic Analysis ,Overcoming Resistance ,Securities Act ,Securities Exchange Act ,Nasdaq Oric ,Oric Pharmaceuticals ,